NeoGenomics (NEO) accounting chief granted new options and RSUs

Rhea-AI Filing Summary

NeoGenomics Inc. Chief Accounting Officer Greg D. Aunan reported equity awards received on March 1, 2026. He was granted 36,825 stock options and 22,889 restricted stock units (RSUs), both with an exercise or acquisition price of $0.00 per share.

The stock options and RSUs each vest ratably over the first three anniversary dates of the grant date, meaning the awards vest in three equal annual installments. Once vested and settled into common shares, the shares of common stock are not subject to expiration. The filing also updates his directly owned option, RSU, and common stock balances as of the same date.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Aunan Greg D

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	36,825	$0.00	--
Grant/Award	Restricted Stock Unit	22,889	$0.00	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Restricted Stock Unit	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Restricted Stock Unit	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 36,825 shares (Direct); Restricted Stock Unit — 22,889 shares (Direct); Common Stock — 22,027 shares (Direct)

Footnotes (1)

1. On March 1, 2026, Mr. Aunan was granted 36,825 stock options. The options vest ratably over the first three anniversary dates of the grant date. On March 1, 2026, Mr. Aunan was granted 22,889 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. Once vested, the shares of common stock are not subject to expiration. On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date. On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aunan Greg D

(Last) (First) (Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS FL 33912

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								22,027	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.83	03/01/2026		A		36,825		(1)	03/01/2036	Common Stock	36,825	$0	36,825	D
Restricted Stock Unit	$0	03/01/2026		A		22,889		(2)	(3)	Common Stock	22,889	$0	22,889	D
Stock Option (Right to Buy)	$14.62							(4)	05/01/2030	Common Stock	28,662		28,662	D
Stock Option (Right to Buy)	$13.96							(5)	05/02/2034	Common Stock	26,978		26,978	D
Restricted Stock Unit	$0							(6)	(3)	Common Stock	16,117		16,117	D
Stock Option (Right to Buy)	$11.86							(7)	02/21/2035	Common Stock	31,163		31,163	D
Restricted Stock Unit	$0							(8)	(3)	Common Stock	12,648		12,648	D

Explanation of Responses:

1. On March 1, 2026, Mr. Aunan was granted 36,825 stock options. The options vest ratably over the first three anniversary dates of the grant date.

2. On March 1, 2026, Mr. Aunan was granted 22,889 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

3. Once vested, the shares of common stock are not subject to expiration.

4. On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date.

5. On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date.

6. On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

7. On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date.

8. On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

Remarks:

	/s/ Ali Olivo, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NeoGenomics (NEO) report for Greg D. Aunan?

NeoGenomics reported that Chief Accounting Officer Greg D. Aunan received equity awards on March 1, 2026. He was granted stock options and restricted stock units as part of his compensation, with details on amounts, vesting schedule, and resulting holdings disclosed.

How many stock options were granted to Greg D. Aunan at NeoGenomics (NEO)?

Greg D. Aunan was granted 36,825 stock options on March 1, 2026. These options vest in three equal annual installments over the first three anniversaries of the grant date, providing long-term incentive tied to NeoGenomics’ share performance.

How many restricted stock units did Greg D. Aunan receive from NeoGenomics (NEO)?

He received 22,889 restricted stock units on March 1, 2026. The RSUs vest ratably over the first three anniversary dates of the grant date, aligning his compensation with NeoGenomics’ future stock performance as units convert into common shares when vested.

What is the vesting schedule for Greg D. Aunan’s new NeoGenomics (NEO) awards?

Both the 36,825 stock options and 22,889 restricted stock units vest ratably over three years. This means one-third of each award vests on each of the first, second, and third anniversaries of the March 1, 2026 grant date, encouraging multi-year retention.

Do Greg D. Aunan’s NeoGenomics (NEO) shares from these awards expire after vesting?

According to the disclosure, once the awards vest and become shares of common stock, those shares are not subject to expiration. The non-expiring nature of the resulting common shares provides ongoing ownership potential for the executive.

What ownership type is reported for Greg D. Aunan’s NeoGenomics (NEO) awards?

The filing shows Greg D. Aunan’s stock options, restricted stock units, and common stock holdings as directly owned. All reported transactions use a direct ownership code, indicating they are held in his name rather than through an external entity or trust.